camparison of two radiotherapy doses of 41.4Gy and 50.4Gy in neoadjuvant chemoradiotherapy of non-metastatic esophageal cancer

camparison of pathologic complete response between two radiotherapy doses of 41.4Gy and 50.4Gy in neoadjuvant chemoradiotherapy of non-metastatic esophageal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250118064427N1

Enrollment

Registered

2025-07-28

Start date

2021-03-03

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: esophageal cancer (SCC or Adenocarcinoma). Condition 2: esophageal cancer. Malignant neoplasm of middle third of esophagus Malignant neoplasm of lower third of esophagus

Interventions

Intervention 1: Control group: 41.4Gy/23 fractions radiation therapy to esophagus and regional lymph nodes with concurrent chemotherapy with carboplatin (AUC:2) and paclitaxel (50mg/m2) followed by su

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: age between 18-70 pathologically proven esophageal cancer (SCC OR ADC) clinical stage T2-4,N0-3 potentially resectable ECOG 0-2

Exclusion criteria

Exclusion criteria: prior chestwall radiation prior induction chemotherapy or unable to receive chemotherapy distant metastasis

Design outcomes

Primary

Measure	Time frame
Pathologic complete response (pCR). Timepoint: after surgery via pathology report. Method of measurement: pathology report.	—

Secondary

Measure	Time frame
Locoregional control. Timepoint: within 24m after treatment every 3m. Method of measurement: endoscopy and CT scan.;Disease free survival. Timepoint: within 2 years of treatment. Method of measurement: CT scan and endoscopy every 3m.;Overall survival (OS). Timepoint: within 2 years of treatment. Method of measurement: patients death in follow up.;Treatment toxicity. Timepoint: weekly in treatment time and every 3m after treatment. Method of measurement: via interview and laboratory tests.	—

Measure

Time frame

Locoregional control. Timepoint: within 24m after treatment every 3m. Method of measurement: endoscopy and CT scan.;Disease free survival. Timepoint: within 2 years of treatment. Method of measurement: CT scan and endoscopy every 3m.;Overall survival (OS). Timepoint: within 2 years of treatment. Method of measurement: patients death in follow up.;Treatment toxicity. Timepoint: weekly in treatment time and every 3m after treatment. Method of measurement: via interview and laboratory tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Nazari

Tehran University of Medical Sciences

rz.nzr.89@gmail.com+98 21 6119 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026